Search

Your search keyword '"Muro K"' showing total 1,234 results
Start Over Author "Muro K"

Refine your results

more »

more »

more »

more »

more »
1,234 results on '"Muro K"'

51. O-6 Gene alterations in ctDNA related to the resistance mechanism of anti-EGFR antibodies and clinical efficacy outcomes of anti-EGFR antibody rechallenge plus trifluridine/tipiracil in metastatic colorectal cancer patients in WJOG8916G trial

Author

Takahashi, N., primary, Izawa, N., additional, Nishio, K., additional, Masuishi, T., additional, Shoji, H., additional, Yamamoto, Y., additional, Matsumoto, T., additional, Sugiyama, K., additional, Kajiwara, T., additional, Kawakami, K., additional, Aomatsu, N., additional, Kawakami, H., additional, Esaki, T., additional, Narita, Y., additional, Hara, H., additional, Horie, Y., additional, Boku, N., additional, Miura, K., additional, Moriwaki, T., additional, Shimokawa, M., additional, Nakajima, T., additional, and Muro, K., additional

Published
2021
Full Text
View/download PDF

52. P-63 MATTERHORN: A phase 3 study of efficacy and safety of neoadjuvant-adjuvant durvalumab and FLOT chemotherapy in resectable gastric and gastroesophageal junction cancer

Author

Janjigian, Y., primary, Van Cutsem, E., additional, Muro, K., additional, Wainberg, Z., additional, Al-Batran, S., additional, Hyung, W., additional, Molena, D., additional, Evans, B., additional, Ruscica, D., additional, Robbins, S., additional, Negro, A., additional, and Tabernero, J., additional

Published
2021
Full Text
View/download PDF

55. Molecular determinants of clinical outcomes with pembrolizumab versus paclitaxel in a randomized, open-label, phase 3 trial in patients with gastroesophageal adenocarcinoma

Author

Shitara, K, Özgüroğlu, M, Bang, Y-J, Di Bartolomeo, M, Mandala', M, Ryu, M-H, Caglevic, C, Chung, H C, Muro, K, Van Cutsem, E, Kobie, J, Cristescu, R, Aurora-Garg, D, Lu, J, Shih, C-S, Adelberg, D, Cao, Z A, and Fuchs, C S

Subjects
tumor mutational burden, gastric cancer, pembrolizumab, chemotherapy, gastroesophageal adenocarcinoma
Published
2021

56. Tumor Response and Symptom Palliation from RAINBOW, a Phase III Trial of Ramucirumab Plus Paclitaxel in Previously Treated Advanced Gastric Cancer

Author

Cascinu, S, Bodoky, G, Muro, K, Van Cutsem, E, Oh, SC, Folprecht, G, Ananda, S, Girotto, G, Wainberg, ZA, Miron, MLL, Ajani, J, Wei, R, Liepa, AM, Carlesi, R, Emig, M, Ohtsu, A, Cascinu, S, Bodoky, G, Muro, K, Van Cutsem, E, Oh, SC, Folprecht, G, Ananda, S, Girotto, G, Wainberg, ZA, Miron, MLL, Ajani, J, Wei, R, Liepa, AM, Carlesi, R, Emig, M, and Ohtsu, A

Abstract

BACKGROUND: In the intent-to-treat (ITT) population of the RAINBOW study, objective response rate (ORR) was 28% and 16% in the ramucirumab and control arms, respectively. To further characterize tumor response, we present details on timing and extent of tumor shrinkage, as well as associations with symptom palliation. MATERIALS AND METHODS: Tumor response was assessed with RECIST v1.1, and quality of life (QoL) was assessed with the European Organization for Research and Treatment of Cancer Quality-of-Life Questionnaire-Core 30 (EORTC QLQ-C30) v3.0. Prespecified and post hoc analyses were conducted in the ITT population, patients with measurable disease, or responders, and included best overall response (BOR), ORR, disease control rate (DCR), duration of response, time to response (TtR), change in tumor size, and associations of QoL with tumor shrinkage and BOR. RESULTS: In both treatment arms, median TtR was 1.5 months. Responses were more durable in the ramucirumab versus control arm (median 4.4 vs. 2.8 months). In patients with measurable disease (78% of ITT), ORR was 36% versus 20%; DCR was 81% versus 61% in the ramucirumab versus control arms. Waterfall plots demonstrated more tumor shrinkage in the ramucirumab versus control arm. Regardless of treatment, tumor response and stable disease were associated with improved or stable QoL, with more tumor shrinkage associated with greater symptom palliation. CONCLUSION: Treatment with ramucirumab plus paclitaxel yielded the highest ORR reported to date for patients with previously treated advanced gastric or gastroesophageal junction adenocarcinoma. Additional details demonstrate robustness of tumor response results. The extent of tumor shrinkage is directly associated with symptom palliation and should be considered when evaluating patient needs and treatment selection. Clinical trial identification number. NCT01170663. IMPLICATIONS FOR PRACTICE: Ramucirumab plus paclitaxel is a recognized standard of care as it impr

Published
2021

57. LBA73 Pathological complete response (pCR) to durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in resectable gastric and gastroesophageal junction cancer (GC/GEJC): Interim results of the global, phase III MATTERHORN study

Author

Janjigian, Y.Y., Al-Batran, S-E., Wainberg, Z.A., Van Cutsem, E., Molena, D., Muro, K., Hyung, W.J., Wyrwicz, L.S., Oh, D-Y., Omori, T., Moehler, M., Garrido, M., Cunha Sousa Oliveira, S., Liberman, M., Castro Oliden, V., Bilici, M., Kurland, J.F., Xynos, I., Mann, H., and Tabernero, J.

Published
2023
Full Text
View/download PDF

62. P-149 QUATTRO-II: A multicenter randomized trial comparing CAPOXIRI + bevacizumab with FOLFOXIRI + bevacizumab as first-line treatment in patients with metastatic colorectal cancer: Efficacy and safety analysis

Author

Kotaka, M., Bando, H., Satake, H., Kotani, D., Hamaguchi, T., Shiozawa, M., Ikumoto, T., Masuishi, T., Yasui, H., Kagawa, Y., Oki, E., Yamamoto, Y., Kawakami, H., Boku, S., Komatsu, Y., Taniguchi, H., Muro, K., Yamazaki, K., Misumi, T., Yoshino, T., Kato, T., and Tsuji, A.

Published
2023
Full Text
View/download PDF

63. P-80 Analysis of plasma angiogenesis factors on the efficacy of FOLFIRI plus ramucirumab and FOLFOXIRI plus ramucirumab as first-line treatment for metastatic colorectal cancer from WJOG9216G randomized phase II study

Author

Yamada, T., Kito, Y., Sakai, K., Nishio, K., Yamazaki, K., Shoji, H., Tsushima, T., Mitani, S., Shiraishi, K., Yasui, H., Hara, H., Shimozaki, K., Esaki, T., Shimokawa, H., Tsuzuki, T., Kajiura, S., Masuishi, T., Baba, E., Yoshimura, K., Kawakami, H., Hironaka, S., and Muro, K.

Published
2023
Full Text
View/download PDF

64. Biomarker analysis beyond angiogenesis: RAS/RAF mutation status, tumour sidedness, and second-line ramucirumab efficacy in patients with metastatic colorectal carcinoma from RAISE—a global phase III study

Author

Yoshino, Takayuki, Portnoy, D. C., Obermannová, R., Bodoky, G., Prausová, J., García-Carbonero, Rocío, Ciuleanu, Tudor Eliade, García-Alfonso, Pilar, Cohn, A. L., Van Cutsem, E., Yamazaki, K., Lonardi, Sara, Muro, K., Kim, T. W., Yamaguchi, K., Grothey, A., O'Connor, J., Taieb, J., Wijayawardana, S. R., Hozak, R. R., Nasroulah, F., Tabernero, J., Vall d'Hebron Institut d'Oncologia, Institut Català de la Salut, [Yoshino T] National Cancer Center Hospital East, Kashiwa, Japan. [Portnoy DC] The West Clinic, Memphis, USA. [Obermannová R] Masarykuv Onkologicky Ustav, Brno, Czech Republic. [Bodoky G] St. Laszlo Hospital, Budapest, Hungary. [Prausová J] Fakultni Nemocnice v MOTOLE, Prague, Czech Republic. [Garcia-Carbonero R] Hospital Hospital Universitario Doce de Octubre, IIS imas12, UCM, CNIO, CIBERONC, Madrid, Spain. [Tabernero J] Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. CIBERONC, Barcelona, Spain, Hospital Universitari Vall d'Hebron, and Vall d'Hebron Barcelona Hospital Campus

Subjects
0301 basic medicine, Neuroblastoma RAS viral oncogene homolog, Oncology, Male, IRINOTECAN, Colorectal cancer, Left, Leucovorin, factores biológicos::biomarcadores::marcadores tumorales [COMPUESTOS QUÍMICOS Y DROGAS], Cetuximab, Other subheadings::/analysis [Other subheadings], GUIDELINES, medicine.disease_cause, DOUBLE-BLIND, 0302 clinical medicine, Còlon - Càncer, Antineoplastic Combined Chemotherapy Protocols, OXALIPLATIN, Neoplasm Metastasis, Neovascularization, Pathologic, Otros calificadores::/análisis [Otros calificadores], COLON-CANCER, Hazard ratio, Neoplasms::Neoplastic Processes::Neoplasm Metastasis [DISEASES], Hematology, CHEMOTHERAPY, neoplasias::neoplasias por localización::neoplasias del sistema digestivo::neoplasias gastrointestinales::neoplasias intestinales::neoplasias colorrectales [ENFERMEDADES], Prognosis, KRAS WILD-TYPE, Survival Rate, Colorectal carcinoma, 030220 oncology & carcinogenesis, FOLFIRI, Recte - Càncer, Female, KRAS, Fluorouracil, Colorectal Neoplasms, Life Sciences & Biomedicine, medicine.medical_specialty, ramucirumab, BEVACIZUMAB, NRAS, Antibodies, Monoclonal, Humanized, Ramucirumab, BRAF, 03 medical and health sciences, Neoplasms::Neoplasms by Site::Digestive System Neoplasms::Gastrointestinal Neoplasms::Intestinal Neoplasms::Colorectal Neoplasms [DISEASES], colorectal carcinoma, left, Internal medicine, Gastrointestinal Tumors, medicine, Biomarkers, Tumor, Humans, Biological Factors::Biomarkers::Biomarkers, Tumor [CHEMICALS AND DRUGS], Survival rate, Aged, Splenic flexure, Science & Technology, business.industry, Marcadors tumorals, Original Articles, medicine.disease, FLUOROURACIL, digestive system diseases, Proto-Oncogene Proteins c-raf, 030104 developmental biology, neoplasias::procesos neoplásicos::metástasis neoplásica [ENFERMEDADES], ANTIBODIES, Mutation, ras Proteins, Camptothecin, business, Follow-Up Studies
Abstract

Carcinoma colorrectal; Ramucirumab; BRAF Carcinoma colorrectal; Ramucirumab; BRAF Colorectal carcinoma; Ramucirumab; BRAF Background Second-line treatment with ramucirumab+FOLFIRI improved overall survival (OS) versus placebo+FOLFIRI for patients with metastatic colorectal carcinoma (CRC) [hazard ratio (HR)=0.84, 95% CI 0.73–0.98, P = 0.022]. Post hoc analyses of RAISE patient data examined the association of RAS/RAF mutation status and the anatomical location of the primary CRC tumour (left versus right) with efficacy parameters. Patients and methods Patient tumour tissue was classified as BRAF mutant, KRAS/NRAS (RAS) mutant, or RAS/BRAF wild-type. Left-CRC was defined as the splenic flexure, descending and sigmoid colon, and rectum; right-CRC included transverse, ascending colon, and cecum. Results RAS/RAF mutation status was available for 85% of patients (912/1072) and primary tumour location was known for 94.4% of patients (1012/1072). A favourable and comparable ramucirumab treatment effect was observed for patients with RAS mutations (OS HR = 0.86, 95% CI 0.71–1.04) and patients with RAS/BRAF wild-type tumours (OS HR = 0.86, 95% CI 0.64–1.14). Among the 41 patients with BRAF-mutated tumours, the ramucirumab benefit was more notable (OS HR = 0.54, 95% CI 0.25–1.13), although, as with the other genetic sub-group analyses, differences were not statistically significant. Progression-free survival (PFS) data followed the same trend. Treatment-by-mutation status interaction tests (OS P = 0.523, PFS P = 0.655) indicated that the ramucirumab benefit was not statistically different among the mutation sub-groups, although the small sample size of the BRAF group limited the analysis. Addition of ramucirumab to FOLFIRI improved left-CRC median OS by 2.5 month over placebo (HR = 0.81, 95% CI 0.68–0.97); median OS for ramucirumab-treated patients with right-CRC was 1.1 month over placebo (HR = 0.97, 95% CI 0.75–1.26). The treatment-by-sub-group interaction was not statistically significant for tumour sidedness (P = 0.276). Conclusions In the RAISE study, the addition of ramucirumab to FOLFIRI improved patient outcomes, regardless of RAS/RAF mutation status, and tumour sidedness. Ramucirumab treatment provided a numerically substantial benefit in BRAF-mutated tumours, although the P-values were not statistically significant. This work was supported by Eli Lilly and Company. No grant number is applicable.

Published
2018

65. Neutropenia and survival outcomes in metastatic colorectal cancer patients treated with trifluridine/tipiracil in the RECOURSE and J003 trials

Author

Yoshino, T, Cleary, JM, Van Cutsem, E, Mayer, RJ, Ohtsu, A, Shinozaki, E, Falcone, A, Yamazaki, K, Nishina, T, Garcia-Carbonero, R, Komatsu, Y, Baba, H, Argiles, G, Tsuji, A, Sobrero, A, Yamaguchi, K, Peeters, M, Muro, K, Zaniboni, A, Sugimoto, N, Shimada, Y, Tsuji, Y, Hochster, HS, Moriwaki, T, Tran, B, Esaki, T, Hamada, C, Tanase, T, Benedetti, F, Makris, L, Yamashita, F, Lenz, H-J, Yoshino, T, Cleary, JM, Van Cutsem, E, Mayer, RJ, Ohtsu, A, Shinozaki, E, Falcone, A, Yamazaki, K, Nishina, T, Garcia-Carbonero, R, Komatsu, Y, Baba, H, Argiles, G, Tsuji, A, Sobrero, A, Yamaguchi, K, Peeters, M, Muro, K, Zaniboni, A, Sugimoto, N, Shimada, Y, Tsuji, Y, Hochster, HS, Moriwaki, T, Tran, B, Esaki, T, Hamada, C, Tanase, T, Benedetti, F, Makris, L, Yamashita, F, and Lenz, H-J

Abstract

BACKGROUND: The phase II J003 (N = 169) and phase III RECOURSE (N = 800) trials demonstrated a significant improvement in survival with trifluridine (FTD)/tipiracil (TPI) versus placebo in patients with refractory metastatic colorectal cancer. This post hoc analysis investigated pharmacokinetic data of FTD/TPI exposure and pharmacodynamic markers, such as chemotherapy-induced neutropenia (CIN) and clinical outcomes. PATIENTS AND METHODS: A total of 210 patients from RECOURSE were enrolled in this substudy. A limited sampling approach was used, with three pharmacokinetic samples drawn on day 12 of cycle 1. Patients were categorized as being above or below the median area under the plasma concentration-time curve (AUC) for FTD and TPI. We conducted a post hoc analysis using the entire RECOURSE population to determine the correlations between CIN and clinical outcome. We then carried out a similar analysis on the J003 trial to validate the results. RESULTS: In the RECOURSE subset, patients in the high FTD AUC group had a significantly increased CIN risk. Analyses of the entire population demonstrated that FTD/TPI-treated patients with CIN of any grade in cycles 1 and 2 had significantly longer median overall survival (OS) and progression-free survival (PFS) than patients who did not develop CIN and patients in the placebo group. Patients who required an FTD/TPI treatment delay had increased OS and PFS versus those in the placebo group and those who did not develop CIN. Similar results were obtained in the J003 cohort. CONCLUSIONS: In RECOURSE, patients with higher FTD drug exposure had an increased CIN risk. FTD/TPI-treated patients who developed CIN had improved OS and PFS versus those in the placebo group and those who did not develop CIN. Similar findings were reported in the J003 cohort, thus validating the RECOURSE results. The occurrence of CIN may be a useful predictor of treatment outcomes for FTD/TPI-treated patients. CLINICALTRIALS. GOV IDENTIFIER: NCT0160795

Published
2020

72. 450P The impact of late-line treatment on overall survival (OS) from the initiation of first-line chemotherapy (CT) for patients (pts) with metastatic colorectal cancer (mCRC): Updated analysis

Author

Kawakami, T., primary, Yamazaki, K., additional, Go, H., additional, Masuishi, T., additional, Kawamoto, Y., additional, Kato, K., additional, Kumanishi, R., additional, Sawada, K., additional, Shirasu, H., additional, Yuki, S., additional, Yamamoto, K., additional, Yamanaka, T., additional, Komatsu, Y., additional, Muro, K., additional, and Yasui, H., additional

Published
2020
Full Text
View/download PDF

73. 104P Angiogenesis-related factors and clinical outcomes in combination therapy with paclitaxel (PTX), ramucirumab (RAM) plus nivolumab (Nivo) for advanced gastric cancer (AGC)

Author

Izawa, N., primary, Ohta, S., additional, Kadowaki, S., additional, Kajiwara, T., additional, Minashi, K., additional, Sunakawa, Y., additional, Muro, K., additional, Nishina, T., additional, Hironaka, S., additional, Yamanaka, T., additional, Nakajima, T.E., additional, and Kawakami, Y., additional

Published
2020
Full Text
View/download PDF

75. O-12 KEYNOTE-061: Response to subsequent therapy following second-line pembrolizumab or paclitaxel in patients with advanced gastric or gastroesophageal junction adenocarcinoma

Author

Yoon, H., primary, Fuchs, C., additional, Özgüroğlu, M., additional, Bang, Y., additional, Bartolomeo, M. Di, additional, Mandala, M., additional, Ryu, M., additional, Fornaro, L., additional, Olesinski, T., additional, Caglevic, C., additional, Chung, H., additional, Muro, K., additional, Cutsem, E. Van, additional, Elme, A., additional, Thuss-Patience, P., additional, Chau, I., additional, Ohtsu, A., additional, Wang, A., additional, Bhagia, P., additional, Lin, J., additional, Shih, C., additional, and Shitara, K., additional

Published
2020
Full Text
View/download PDF

77. P-163 Systemic chemotherapy for previously treated metastatic small bowel adenocarcinoma

Author

Nakazawa, T., primary, Narita, Y., additional, Kumanishi, R., additional, Ogata, T., additional, Matsubara, Y., additional, Nozawa, K., additional, Kato, K., additional, Honda, K., additional, Masuishi, T., additional, Bando, H., additional, Kadowaki, S., additional, Ando, M., additional, Hara, K., additional, Tajika, M., additional, and Muro, K., additional

Published
2020
Full Text
View/download PDF

78. LBA-4 Updated analysis of DELIVER trial (JACCRO GC-08): A large observational/translational study of nivolumab treatment in advanced gastric cancer

Author

Sunakawa, Y., primary, Sakamoto, Y., additional, Inoue, E., additional, Kawabata, R., additional, Ishiguro, A., additional, Akamaru, Y., additional, Kito, Y., additional, Takahashi, M., additional, Matsuyama, J., additional, Yabusaki, H., additional, Makiyama, A., additional, Suzuki, T., additional, Tsuda, M., additional, Yasui, H., additional, Hirabayashi, N., additional, Takeno, A., additional, Kawakami, H., additional, Matoba, R., additional, Muro, K., additional, Nakajima, T., additional, Ichikawa, W., additional, and Fujii, M., additional

Published
2020
Full Text
View/download PDF

80. Biomarker analyses of second-line ramucirumab in patients with advanced gastric cancer from RAINBOW, a global, randomized, double-blind, phase 3 study

Author

Van Cutsem, E., primary, Muro, K., additional, Cunningham, D., additional, Bodoky, G., additional, Sobrero, A., additional, Cascinu, S., additional, Ajani, J., additional, Oh, S.C., additional, Al-Batran, S.E., additional, Wainberg, Z.A., additional, Wijayawardana, S.R., additional, Melemed, S., additional, Ferry, D., additional, Hozak, R.R., additional, and Ohtsu, A., additional

Published
2020
Full Text
View/download PDF

81. Neutropenia and survival outcomes in metastatic colorectal cancer patients treated with trifluridine/tipiracil in the RECOURSE and J003 trials

Author

Yoshino, T., primary, Cleary, J.M., additional, Van Cutsem, E., additional, Mayer, R.J., additional, Ohtsu, A., additional, Shinozaki, E., additional, Falcone, A., additional, Yamazaki, K., additional, Nishina, T., additional, Garcia-Carbonero, R., additional, Komatsu, Y., additional, Baba, H., additional, Argilés, G., additional, Tsuji, A., additional, Sobrero, A., additional, Yamaguchi, K., additional, Peeters, M., additional, Muro, K., additional, Zaniboni, A., additional, Sugimoto, N., additional, Shimada, Y., additional, Tsuji, Y., additional, Hochster, H.S., additional, Moriwaki, T., additional, Tran, B., additional, Esaki, T., additional, Hamada, C., additional, Tanase, T., additional, Benedetti, F., additional, Makris, L., additional, Yamashita, F., additional, and Lenz, H.-J., additional

Published
2020
Full Text
View/download PDF

83. Age does not influence efficacy of ramucirumab in advanced gastric cancer: Subgroup analyses of REGARD and RAINBOW

Author

Muro K., Cho J. Y., Bodoky G., Goswami C., Chao Y., dos Santos L. V., Shimada Y., Topuzov E., Van Cutsem E., Tabernero J., Zalcberg J., Chau I., Cascinu S., Cheng R., Hsu Y., Emig M., Orlando M., Fuchs C., Muro, K., Cho, J. Y., Bodoky, G., Goswami, C., Chao, Y., dos Santos, L. V., Shimada, Y., Topuzov, E., Van Cutsem, E., Tabernero, J., Zalcberg, J., Chau, I., Cascinu, S., Cheng, R., Hsu, Y., Emig, M., Orlando, M., and Fuchs, C.

Subjects
Adult, Male, gastroesophageal neoplasms, Paclitaxel, ramucirumab, Adenocarcinoma, Antibodies, Monoclonal, Humanized, elderly, Young Adult, Double-Blind Method, Stomach Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Humans, Aged, Neoplasm Staging, Randomized Controlled Trials as Topic, Aged, 80 and over, Age Factors, vascular endothelial growth factor receptor-2, Antibodies, Monoclonal, Middle Aged, Placebo Effect, young patients, Survival Rate, Treatment Outcome, Clinical Trials, Phase III as Topic, Female, Esophagogastric Junction
Abstract

Background and Aim: REGARD and RAINBOW were global, phase 3, randomized, double-blind trials of second-line ramucirumab for metastatic gastric or gastroesophageal junction adenocarcinoma. Exploratory subgroup analyses were described to assess the efficacy and safety of ramucirumab in REGARD and RAINBOW in young (≤45 and

Published
2018

93. 40. Fuchs CS, Doi T, Jang RW, Muro K, Satoh T, Machado M, Sun W, Jalal SI, Shah MA, Metges JP, Garrido M, Golan T, Mandala M, Wainberg ZA, Catenacci DV, Ohtsu A, Shitara K, Geva R, Bleeker J, Ko AH, Ku G, Philip P, Enzinger PC, Bang YJ, Levitan D, Wang J, Rosales M, Dalal RP, Yoon HH

Author

Fuchs, Cs, Doi, T, Jang, Rw, Muro, K, Satoh, T, Machado, M, Sun, W, Jalal, Si, Shah, Ma, Metges, Jp, Garrido, M, Golan, T, Mandala', M, Wainberg, Za, Catenacci, Dv, Ohtsu, A, Shitara, K, Geva, R, Bleeker, J, Ko, Ah, Ku, G, Philip, P, Enzinger, Pc, Bang, Yj, Levitan, D, Wang, J, Rosales, M, Dalal, Rp, and Yoon, Hh.

Published
2018

94. KEYNOTE-181: Pembrolizumab vs chemotherapy in patients (pts) with advanced/metastatic adenocarcinoma (AC) or squamous cell carcinoma (SCC) of the esophagus as second-line (2L) therapy

Author

Kim, S.-B., primary, Doi, T., additional, Kato, K., additional, Chen, J., additional, Shah, M., additional, Adenis, A., additional, Luo, S., additional, Qin, S., additional, Kojima, T., additional, Metges, J.-P., additional, Francois, E., additional, Muro, K., additional, Cheng, Y., additional, Li, Z., additional, Yuan, X., additional, Wang, R., additional, Cui, Y., additional, Bhagia, P., additional, and Shen, L., additional

Published
2019
Full Text
View/download PDF

95. Interim analysis of an observational/translational study for nivolumab treatment in advanced gastric cancer: JACCRO GC-08 (DELIVER trial)

Author

Sunakawa, Y., primary, Takahashi, Y., additional, Inoue, E., additional, Sakamoto, Y., additional, Kawabata, R., additional, Yabusaki, H., additional, Matsuyama, J., additional, Ishiguro, A., additional, Takahashi, M., additional, Akamaru, Y., additional, Kito, Y., additional, Makiyama, A., additional, Yasui, H., additional, Kawakami, H., additional, Nakajima, T.E., additional, Muro, K., additional, Matoba, R., additional, Ichikawa, W., additional, and Fujii, M., additional

Published
2019
Full Text
View/download PDF

96. The impact of late-line treatment on overall survival (OS) from the initiation of first-line chemotherapy (CT) for patients (pts) with metastatic colorectal cancer (mCRC)

Author

Kawakami, T., primary, Masuishi, T., additional, Kawamoto, Y., additional, Go, H., additional, Shirasu, H., additional, Kato, K., additional, Kumanishi, R., additional, Sawada, K., additional, Yamamoto, K., additional, Yuki, S., additional, Komatsu, Y., additional, Yasui, H., additional, Muro, K., additional, Yamanaka, T., additional, and Yamazaki, K., additional

Published
2019
Full Text
View/download PDF

97. Randomized phase II trial of weekly paclitaxel + ramucirumab versus weekly nab-paclitaxel + ramucirumab for unresectable advanced or recurrent gastric cancer with peritoneal dissemination refractory to first-line therapy: WJOG10617G/P-SELECT

Author

Hirata, K., primary, Hamamoto, Y., additional, Tsuchihashi, K., additional, Kondoh, C., additional, Yamazaki, K., additional, Hironaka, S., additional, Ando, M., additional, Imamura, C.K., additional, Yoshimura, K., additional, and Muro, K., additional

Published
2019
Full Text
View/download PDF

98. Impact of pembrolizumab (pembro) versus paclitaxel on health-related quality of life (HRQoL) in patients with advanced gastric or gastroesophageal junction (GEJ) cancer that has progressed after first-line chemotherapy (KEYNOTE-061)

Author

Van Cutsem, E., primary, Amonkar, M., additional, Fuchs, C.S., additional, Alsina, M., additional, Özgüroğlu, M., additional, Bang, Y.-J., additional, Chung, H.C., additional, Muro, K., additional, Goekkurt, E., additional, Benson, A., additional, Sun, W., additional, Wainberg, Z.A., additional, Norquist, J., additional, Chen, X., additional, Shih, C.-S., additional, and Shitara, K., additional

Published
2019
Full Text
View/download PDF

99. The phase 3 KEYNOTE-181 study: pembrolizumab versus chemotherapy as second-line therapy for advanced esophageal cancer

Author

Metges, J., primary, François, E., additional, Shah, M., additional, Adenis, A., additional, Enzinger, P., additional, Kojima, T., additional, Muro, K., additional, Bennouna, J., additional, Hsu, C., additional, Moriwaki, T., additional, Kim, S., additional, Lee, S., additional, Kato, K., additional, Shen, L., additional, Qin, S., additional, Ferreira, P., additional, Wang, R., additional, Bhagia, P., additional, Kang, S., additional, and Doi, T., additional

Published
2019
Full Text
View/download PDF

100. PARADIGM study: A multicenter, randomized, phase III study of mFOLFOX6 plus panitumumab or bevacizumab as first-line treatment in patients with RAS (KRAS/NRAS) wild-type metastatic colorectal cancer

Author

Muro, K., primary, Uetake, H., additional, Tsuchihara, K., additional, Shitara, K., additional, Yamazaki, K., additional, Ota, M., additional, Oki, E., additional, Sato, T., additional, Naitoh, T., additional, Komatsu, Y., additional, Kato, T., additional, Yamanaka, K., additional, Mori, I., additional, Soeda, J., additional, Hihara, M., additional, Yamanaka, T., additional, Akagi, K., additional, Ochiai, A., additional, and Yoshino, T., additional

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results